Prof Giorgos Bamias, MD, PhD
Gastroenterology — Sotiria General Hospital, Greece
Giorgos Bamias
LeadR Profile
Gastroenterology
Subspecialties: Biochemistry - Nutrition - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2002 - 2026
Number : 207
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| B cells regulate T cell transfer colitis by partially reconstituting luminal IgA and modulating the colonic microbiota. cytokines, cells, colitis, crohn disease, inflammatory bowel diseases, immunoglobulin a, secretory, t-lymphocytes, b-lymphocytes, colitis, ulcerative, interleukin-10, microbiota | Inflamm Bowel Dis | 2026 | 0 |
| Efficacy and Safety of Ozanimod in Ulcerative Colitis: A Real-World Pan-Hellenic Study. colitis, safety, treatment failure, inflammatory bowel diseases, therapeutics, colitis, ulcerative | Medicina (Kaunas) | 2026 | 0 |
| Vedolizumab clinical decision support tool predicts clinically relevant targets in patients with Crohn's disease. quality of life, crohn disease, probability, therapeutics | Ther Adv Gastroenterol | 2026 | 0 |
| Predictors of Response to Induction Therapy with Ustekinumab in Patients with Ulcerative Colitis: Results from a National Study in Greece. ustekinumab, colitis, probability, biomarkers, therapeutics, blood platelets, colitis, ulcerative | Diseases | 2026 | 0 |
| The Therapeutic Potential of Targeting TL1A in a Spectrum of Inflammatory Disorders. cytokines, antibodies, antibodies, monoclonal, therapeutics, autoimmunity | J Inflamm Res | 2026 | 0 |
Clinical Studies 25
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy and Safety of JNJ 78934804 in Participants With Moderately to Severely Active Crohn s Disease 2026-525922-39-00 — safety, crohn disease | Phase 3 | Not yet recruiting | 2026 |
| Efficacy and Safety of JNJ 78934804 in Participants with Moderately to Severely Active Ulcerative Colitis 2026-525923-26-00 — colitis, safety, colitis, ulcerative | Phase 3 | Recruiting | 2026 |
| A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn s disease 2025-521037-86-00 — safety, crohn disease, maintenance, immune system diseases, immune system | Phase 3 | Recruiting | 2026 |
| An Adaptive Dose Ranging Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis 2023-507853-13-00 — colitis, therapeutics, colitis, ulcerative | Phase 2 | Active not recruiting | 2025 |
| A clinical trial of MK 8690 in people with ulcerative colitis (MK 8690 002) 2025-523479-49-00 — colitis, safety, colitis, ulcerative | Phase 2 | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map